You are here

Pfizer Declares First-Quarter 2015 Dividend

Board of Directors Approves Increase in Quarterly Cash Dividend to $0.28 Per Share

Monday, December 15, 2014 - 12:06pm
EST

The board of directors of Pfizer Inc. today declared a 28-cent first-quarter 2015 dividend on the company’s common stock, payable March 3, 2015, to shareholders of record at the close of business on February 6, 2015. Pfizer increased the dividend by approximately 8 percent, to 28 cents from 26 cents per share.

 

The first-quarter 2015 cash dividend will be the 305th consecutive quarterly dividend paid by Pfizer.

“The dividend increase demonstrates our commitment to returning capital to shareholders and is supported by our continued confidence in the business,” stated Ian Read, Pfizer chairman and chief executive officer. “We remain focused on maximizing total shareholder return, of which the dividend is a key component. In addition, we continue to expect to repurchase approximately $5.0 billion of our common stock in 2014, with more than $11 billion of share repurchase authorization available in 2015 and beyond.”

About Pfizer Inc.

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com.

DISCLOSURE NOTICE: The information contained in this release is as of December 15, 2014. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about the Company’s expected share repurchases that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties and variables inherent in business and financial planning, including among other things, the risk of unforeseen business, financial or other events that could impact the Company’s ability to implement share repurchases as currently planned.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the SEC and available at www.sec.gov and www.pfizer.com.

 

Contact: 

Pfizer Inc.

Media Contact:

Joan Campion, 212-733-2798

or

Investor Contact:

Ryan Crowe, 212-733-8160